Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN FRANCISCO, AUG. 11, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

OLEMA ONCOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS

SAN FRANCISCO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 130,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF AUGUST 1, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

OLEMA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN FRANCISCO, JULY 02, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 154,500 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF JULY 1, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, JUNE 03, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO 11 NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 322,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF JUNE 2, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, MAY 28, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED IT HAS ALIGNED WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO SELECT 90 MG OF PALAZESTRANT AS THE DOSE FOR PART 2 OF THE ONGOING REGISTRATIONAL PHASE 3 OPERA-01 TRIAL IN SECOND- AND THIRD-LINE ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (ER+/HER2-) METASTATIC BREAST CANCER. THIS UPDATE WILL BE PRESENTED AS PART OF THE OPERA-01 TRIAL-IN-PROGRESS POSTER AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING TAKING PLACE MAY 30-JUNE 3 IN CHICAGO, ILLINOIS. THE FDA ALSO SELECTED 90 MG OF PALAZESTRANT IN COMBINATION WITH THE APPROVED DOSE OF CDK4/6 INHIBITOR RIBOCICLIB FOR THE PIVOTAL PHASE 3 OPERA-02 TRIAL IN FRONTLINE ER+/HER2- METASTATIC BREAST CANCER.

OLEMA ONCOLOGY ANNOUNCES PALAZESTRANT DOSE SELECTION AND TRIAL-IN-PROGRESS POSTER AT ASCO 2025 ANNUAL MEETING

SAN FRANCISCO, MAY 21, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

OLEMA ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

PIVOTAL PHASE 3 OPERA-02 TRIAL OF PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN FRONTLINE METASTATIC BREAST CANCER ON TRACK FOR INITIATION IN 2025, SUPPORTED BY PROMISING UPDATED EFFICACY DATA FROM ONGOING PHASE 1B/2 STUDY PIVOTAL PHASE 3 OPERA-01 TRIAL OF PALAZESTRANT MONOTHERAPY IN 2/3L METASTATIC BREAST CANCER CONTINUES TO ADVANCE WITH TOP-LINE DATA ANTICIPATED IN 2026; TRIAL-IN-PROGRESS POSTER TO BE HIGHLIGHTED AT ASCO ANNUAL MEETING PRECLINICAL DATA FOR OP-3136 PRESENTED AT AACR DEMONSTRATING ANTI-TUMOR ACTIVITY IN OVARIAN, NON-SMALL CELL LUNG, AND PROSTATE CANCER MODELS; PHASE 1 TRIAL RECRUITMENT ONGOING ENDED THE FIRST QUARTER WITH $392.7 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES SAN FRANCISCO, MAY 13, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. DURING THE FIRST QUARTER, WE CONTINUED TO MAKE IMPORTANT OPERATIONAL PROGRESS ADVANCING OUR PIPELINE AND WE ENTER THE SECOND QUARTER WELL-POSITIONED ACROSS THE BUSINESS, SAID SEAN P.

OLEMA ONCOLOGY REPORTS FIRST QUARTER 2025 FINANCIAL AND OPERATING RESULTS

SAN FRANCISCO, MAY 09, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC.(OLEMA, OLEMA ONCOLOGY, NASDAQ: OLMA) A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

SAN FRANCISCO, MAY 02, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 104,400 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF MAY 1, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, APRIL 25, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED PRECLINICAL DATA DEMONSTRATING THE ANTI-TUMOR ACTIVITY OF OP-3136, A NOVEL SMALL MOLECULE THAT POTENTLY AND SELECTIVELY INHIBITS LYSINE ACETYLTRANSFERASE 6 (KAT6), IN PROSTATE, OVARIAN, AND NON-SMALL CELL LUNG CANCER (NSCLC) MODELS. THESE FINDINGS ARE BEING PRESENTED IN A LATE-BREAKING POSTER SESSION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING TAKING PLACE APRIL 25-30 IN CHICAGO, ILLINOIS.

Olema Pharmaceuticals, Inc.

OLMA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Olema Pharmaceuticals, Inc.

OLMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OLMA